akhatri

Eaststone Limited is initiating a recall of all batches of quetiapine oral suspension products due to a potential risk of overdose, which could have consequences for the safety of patients. This alert is for action by: ​primary and secondary care, specifically those involved in pharmacy services, including dispensing general practices and those involved in the prescribing for mental health conditions. This is [...]

The post National Patient Safety Alert: Class 1 Medicines Recall Notification: Recall of Quetiapine Oral Suspension (unlicensed medicine), manufactured by Eaststone Limited appeared first on Community Pharmacy England.

The Medicines and Healthcare products Regulatory Agency (MHRA) has issued a Drug Safety Alert regarding Glucagon-Like Peptide-1 (GLP-1) receptor agonists and dual GLP-1/glucose-dependent insulinotropic polypeptide (GIP) receptor agonists. The product information for all GLP-1 receptor agonists and dual GLP-1/GIP receptor agonists (dulaglutide, exenatide, liraglutide, semaglutide and tirzepatide) has been further updated to highlight the potential [...]

The post MHRA Drug Safety Update: GLP-1 receptor agonists and dual GLP-1/GIP receptor agonists: strengthened warnings appeared first on Community Pharmacy England.

The NHS Business Services Authority (NHSBSA) produces a quarterly newsletter called “Hints & Tips for dispensing contractors”. The latest edition (Issue 62) contains some useful information and advice on: New address for end of month batch submissions Pharmacy Quality Scheme: Declaration window opens in Manage Your Service on 2 February 2026 Pharmacy Quality Scheme: Antimicrobial [...]

The post NHSBSA ‘Hints & Tips’ – Issue 62 appeared first on Community Pharmacy England.

The Commission on Human Medicines (CHM) has endorsed changes to the risk minimisation measures for isotretinoin, following a review of the impact of the measures implemented in 2023. We ask healthcare professionals to review these new measures and supporting materials and integrate them into their clinical practice. Second prescriber no longer required plus updated risk [...]

The post MHRA Drug Safety Update: Isotretinoin – changes to prescribing guidance and additional risk minimisation measures appeared first on Community Pharmacy England.

The Department of Health and Social Care (DHSC) has confirmed that the Serious Shortage Protocols (SSP) for Adipine® XL 30mg MR tablets (SSP084) and Adipine® XL 60mg MR tablets (SPP085) will expire at 23:59pm Friday 23rd January 2026. SSP 084 and SSP085 were originally set to expire on 6th February 2026 however, the expiry has been [...]

The post Expiry of SSP084 Adipine® XL 30mg MR tablets and SSP085 Adipine® XL 60mg MR tablets appeared first on Community Pharmacy England.